Drug delivery companies develop technologies, formulations and platforms that control how, where and when therapeutic agents are released in the body. The field focuses on improving treatment efficacy, reducing side effects and helping medicines reach their intended targets safely and efficiently.
This category includes companies working on:
Browse 119 UK drug delivery companies below.
VNAR antibody shuttles for brain-targeted biologic therapies
Ossianix is a biopharmaceutical company developing single-domain VNAR antibody platforms for targeted delivery of therapeutics across the blood-brain barrier. Its TXP1 shuttle binds transferrin receptor 1 to transport antibody-based medicines into the central nervous system. The company engineers antibody fusions and…
Silicon-based RNA delivery platform for rare disease therapeutics
SiSaf is a biopharmaceutical company developing RNA therapeutics using its proprietary platform, which combines bioabsorbable silicon with organic lipid materials to improve the stability, safety, and transfection efficiency of nucleic acid payloads. The platform addresses known limitations of conventional lipid…
Targeted nanoparticle formulations for nucleic acid delivery
XapHe is a biotechnology company developing peptide-based nanoparticles for therapeutic nucleic acid delivery. Its HAWC platform packages RNA and DNA payloads into formulations designed for cell entry and tissue targeting. The company supplies transfection kits and offers custom nanoparticle formulation services for…
Oral delivery platform for biologics targeting inflammatory diseases
Intract Pharma is a biotechnology company developing proprietary formulation platforms for the oral delivery of complex biologics including monoclonal antibodies and proteins. The technology enables precision delivery to the colon for local and systemic immunomodulation, targeting gastrointestinal and systemic…
Stabilised siRNA therapeutics platform targeting cardiovascular gene silencing
Argonaute RNA is a biopharmaceutical company developing small interfering RNA therapeutics for cardiovascular disease. Its siRNA platform uses proprietary chemical stabilisation to enable safe, targeted and temporary gene silencing in specific tissue cells, overcoming delivery and safety barriers that have constrained…
Topical formulations treating atopic dermatitis and inflammatory skin disease
Quodria is a dermatology-focused biotech developing novel topical formulations for skin diseases using nanotechnology-enabled drug delivery. Its lead programme, Q001, is a small molecule galectin-3 inhibitor licensed from University of Liverpool spin-out Galytx, in development as a first-in-class topical treatment for…
Aerosol technology for inhaled drug formulation development
Microsol is a Bristol-based technology company developing advanced measurement and computational tools for aerosol characterisation in respiratory drug delivery. Its platform combines single-particle measurement capabilities with predictive simulations to analyse evaporation kinetics, hygroscopicity, and morphology…
Proprietary formulation platform enhancing diabetes and cardiometabolic therapies
Arecor Therapeutics is a biopharmaceutical company developing enhanced formulations of existing therapeutic products for diabetes and cardiometabolic diseases. Its proprietary formulation technology improves stability, concentration and delivery profiles for biologics and peptides, supporting both in-house programmes…
Non-invasive small molecule eye drops for retinal vascular disease
Foventa is a biopharmaceutical company developing non-invasive, small molecule therapeutics for retinal vascular diseases that can cause vision loss. Its lead candidate targets VEGF splicing, a mechanism underlying abnormal blood vessel growth in conditions including diabetic retinopathy and diabetic macular oedema.…
Ultrasound-based platform to enhance drug delivery into solid tumours
OxSonics is a clinical-stage biotechnology company developing a proprietary drug delivery platform that uses focused ultrasound and injectable cavitation particles to enhance the penetration of anti-cancer agents into solid tumours. The system requires no drug reformulation and includes real-time acoustic mapping to…
Specialty pharma delivering niche medicines and novel drug delivery technology
Therakind is a specialty pharmaceutical company focused on developing niche medicines for difficult-to-treat patient populations, including children and the elderly. The company has obtained regulatory approvals for three products across the FDA, EMA and MHRA, and has developed a proprietary intranasal dry powder…
Biopharmaceutics and dissolution consultancy for drug product development
Biowaived is a contract research organisation providing biopharmaceutics and dissolution expertise to pharmaceutical and biotechnology companies. The company offers consultancy and laboratory-based experimental services spanning dissolution method development, physicochemical characterisation of active pharmaceutical…
Single-particle Raman analysis platform for nanoformulation characterisation
SPARTA Biodiscovery is an analytical technology company developing a benchtop instrument using Raman spectroscopy and optical trapping to characterise individual nanoparticles in a label-free, automated, high-throughput process. The platform provides chemical composition, drug loading, and stability data at the…
In vitro skin penetration and dermal absorption contract research
An-eX Analytical Services is an independent contract research organisation specialising in in vitro dermal absorption and skin penetration science. The company provides human skin penetration and permeation studies conducted to OECD 428 and related guidelines, alongside in vitro release testing, analytical method…
Sustainable conjugation technology for antibody-drug conjugate manufacturing
Vitamab is a Manchester-based biotechnology company developing conjugation technology to strengthen the antibody-drug conjugate manufacturing supply chain. Its proprietary system uses accessible, lower-toxicity materials in place of scarce or hazardous reagents, aiming to reduce production costs and environmental…
Generic, branded and biosimilar medicines across global therapeutic areas
Viatris UK Healthcare is the UK subsidiary of Viatris Inc., a global pharmaceutical company formed in 2020 through the combination of Mylan and Pfizer's Upjohn division. Operating from sites in Hertfordshire, Cambridge, and Sandwich, Kent, the UK entity carries out formulation and device research and development,…
Protein superglue vaccine platform targeting infectious disease and cancer
SpyBiotech is a clinical-stage biotechnology company developing vaccines using its proprietary protein superglue technology, which enables efficient and stable attachment of antigens to virus-like particle and viral vector delivery platforms. The approach improves immunogenicity and reduces manufacturing complexity…
Sustained-release ocular drug delivery for retinal disease
Re-Vana Therapeutics is a biotechnology company developing sustained-release drug delivery technologies for the treatment of serious retinal diseases. Its biodegradable hydrogel platform uses photo-crosslinking to form in-situ implants administered via intravitreal injection, enabling controlled release of biologics,…
Nitric oxide therapeutics developer for infectious and respiratory disease
30 Technology is a clinical-stage biopharmaceutical company developing nitric oxide-generating therapies for the treatment of antimicrobial-resistant infections and chronic respiratory diseases. The company’s proprietary platform enables controlled, sustained delivery of nitric oxide across inhaled, topical and powder…